GLMD — Galmed Pharmaceuticals Ltd.

Summary of GLMD Q4 2021 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $7.5 million for Q4 2021, compared to $10.3 million in Q4 2020.
• Annual Net Loss: $32.5 million for the full year 2021, up from $28.8 million in 2020.
• Loss Per Share: $0.13 for Q4 2021, down from $0.48 in Q4 2020; $1.32 for the full year, slightly up from $1.35 in 2020.
• Research and Development Expenses: $6.3 million for Q4 2021, down from $9 million in Q4 2020; $27.2 million for the full year, up from $26.1 million in 2020.
• General and Administrative Expenses: $1.2 million for Q4 2021, slightly down from $1.3 million in Q4 2020; $5.7 million for the full year, up from $4.1 million in 2020.
• Cash Position: $34.9 million as of December 31, 2021, down from $51 million at the end of 2020.

2. Strategic Updates and Business Highlights

• ARMOR Phase 3 Study: Interim results from the open-label portion showed promising anti-fibrotic effects of Aramchol, with significant fibrosis improvement rates (40% to 100% depending on the assessment method).
• Regulatory Strategy: The initiation of the double-blind, placebo-controlled part of the Phase 3 study is pushed to the second half of 2023 due to unresolved uncertainties regarding primary endpoints and regulatory guidance.
• Intellectual Property: New patents granted for Aramchol extend protection until December 2038, enhancing its competitive position.
• Amilo-5MER Development: Positive Phase 1 results reported; the company is exploring potential proof-of-concept studies and partnerships for further development.

3. Forward Guidance and Outlook

• Phase 3 Study Timeline: The company plans to initiate the registrational study in the second half of 2023, contingent on resolving current uncertainties and securing sufficient funding.
• Focus on AI and Biomarkers: Ongoing efforts to integrate AI in histological assessments to improve sensitivity and accuracy in fibrosis detection.

4. Challenges and Points of Concern

• High Screen Failure Rates: The company faces significant challenges with a high screen failure rate (80-90%) in NASH studies, complicating patient recruitment.
• Regulatory Uncertainties: The lack of validated non-invasive biomarkers and a clear primary endpoint for NASH drugs pose risks to the clinical development timeline.
• Market Competition: The competitive landscape for NASH treatments is evolving, necessitating strategic adjustments to maintain an edge.

5. Notable Q&A Insights

• Histology Data: Questions raised about the differences in fibrosis improvement rates between 24 and 48-week cohorts, with management indicating that small sample sizes limit conclusions.
• Regulatory Discussions: Management emphasized the need for ongoing dialogue with the FDA regarding methodologies for assessing fibrosis improvement, highlighting the importance of AI in future studies.
• Partnership Potential: Management is open to collaborations for further development of Amilo-5MER, recognizing the value of partnerships in advancing clinical studies.

Overall, Galmed is navigating a complex landscape with promising clinical data but faces significant regulatory and operational challenges that could impact its development timelines and market positioning.